Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation

被引:76
作者
Holmes, C
Ballard, C
Lehmann, D
Smith, AD
Beaumont, H
Day, IN
Khan, MN
Lovestone, S
McCulley, M
Morris, CM
Munoz, DG
O'Brien, K
Russ, C
Del Ser, T
Warden, D
机构
[1] Univ Southampton, Moorgreen Hosp, Memory Assessment & Res Ctr, Clin Neurosci Res Div, Southampton, Hants, England
[2] Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
[3] Univ Oxford, Dept Pharmacol, OPTIMA, Oxford OX1 3QT, England
[4] Radcliffe Infirm, Oxford OX2 6HE, England
[5] Inst Psychiat, London, England
[6] Dept Neurol, Madrid, Spain
[7] Univ Western Ontario, London, ON N6A 3K7, Canada
关键词
D O I
10.1136/jnnp.2004.039321
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine whether individuals with Alzheimer's disease ( AD) and the K variant allele of butyrylcholinesterase have a slower rate of cognitive decline than those without the K variant allele of butyrylcholinesterase. Method: The cognitive status of 339 community based subjects with AD was assessed with the Mini Mental State Examination at baseline and yearly over a three year follow up period. The rates of cognitive decline of subjects with and without the K variant allele were compared. Result: Presence of the K allele was associated with a slower average rate of cognitive decline in subjects with severe AD. Conclusions: This finding is consistent with the suggestion that the K variant of butyrylcholinesterase has an important role in disease progression in AD, and this may have implications for treatment.
引用
收藏
页码:640 / 643
页数:4
相关论文
共 23 条
  • [1] BARTELS CF, 1992, AM J HUM GENET, V50, P1086
  • [2] FACTORS AFFECTING SURVIVAL IN ALZHEIMERS-DISEASE
    BURNS, A
    LEWIS, G
    JACOBY, R
    LEVY, R
    [J]. PSYCHOLOGICAL MEDICINE, 1991, 21 (02) : 363 - 370
  • [3] Variability in annual mini-mental state examination score in patients with probable Alzheimer disease -: A clinical perspective of data from the consortium to establish a registry for Alzheimer's disease
    Clark, CM
    Sheppard, L
    Fillenbaum, GG
    Galasko, D
    Morris, JC
    Koss, E
    Mohs, R
    Heyman, A
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (07) : 857 - 862
  • [4] COREY BJ, 2000, DEMENTIA, V34, P405
  • [5] MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN
    FOLSTEIN, MF
    FOLSTEIN, SE
    MCHUGH, PR
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) : 189 - 198
  • [6] CHOLINESTERASES AND THE PATHOLOGY OF ALZHEIMER-DISEASE
    GEULA, C
    MESULAM, MM
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1995, 9 : 23 - 28
  • [7] Giacobini E., 2000, CHOLINESTERASES CHOL
  • [8] Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications
    Holmes, C
    Lovestone, S
    [J]. AGE AND AGEING, 2003, 32 (02) : 200 - 204
  • [9] Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies
    Holmes, C
    Cairns, N
    Lantos, P
    Mann, A
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 : 45 - 50
  • [10] Genotype and phenotype in Alzheimer's disease
    Holmes, C
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2002, 180 : 131 - 134